This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
DrugPricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the DrugPricing Transparency Congress on March 28-29, 2022! Visit www.informaconnect.com/drug-pricing-transparency for further details and to register.
Experts from across the industry will discuss how current and future drugpricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*
Time for the Drug Channels annual reality check on drugpricing. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by almost 9%. d/b/a Drug Channels Institute.
Separately, the drugmaker agreed to pay $25 million to settle charges of participating in a price-fixing scheme with other generic companies. At the same time, Teva steadily raised the price of its drug by thousands of dollars.
Time for the Drug Channels annual reality check on drugpricing. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. The factors behind declining drugprices will remain in the coming years—and become even stronger due to forthcoming changes in Medicare and Medicaid.
Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. It's time for Drug Channels ’ annual reality check on U.S. drugpricing. For 2023, brand-name drugs’ list prices again grew at mid-single-digit rates. However, net prices dropped for an unprecedented sixth consecutive year.
In this issue: An update on the retail pharmacy shakeout Arguing for high drugprices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave Grohl fights for your right to…have healthcare price transparency? Sorry, no Threads.) All rights reserved.
The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drugpricing system. to 1:30 p.m.
See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards. In the video below, I discuss how generic drugpricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute.
The company took advantage of the lack of generic competitors on the market to charge the NHS “excessive and unfair prices” for liothyronine, which meant that NHS spending on the drug swelled from £600,000 in 2006 to more than £30 million by 2016.
Minnesota just released the industry‘s first ever mandated financial report on the 340B DrugPricing Program. During next week’s Drug Channels Outlook 2025 live video webinar, he'll tell you what's ahead for the program that continues to defy gravity. It’s time to pay attention to the money behind the 340B curtain.
It was another year of unexpected drugprice developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. I also review the factors behind declining brand-name drugprices.
And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drugprices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.
When rebates and discounts were factored in, brand-name drugprices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. That’s why I refer to them as drugpricing flat earthers (#DPFE).
It was another year of unexpected drugprice developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. I also review the factors behind declining brand-name drugprices.
When rebates and discounts were factored in, brand-name drugprices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. That’s why I refer to them as drugpricing flat earthers (#DPFE).
When Americans complains about “drugprices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.
This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. When Americans complain about “drugprices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel.
Vishali discusses the persistent challenges of duplicate discounts between the 340B DrugPricing Program and the Medicaid Drug Rebate Program. To learn more, sign up now for priority access to Kalderos’ 2023 annual report: Mission Critical: Bringing Drug Discount Stakeholders Together so Patients Win.
Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drugpricing, reimbursement, and dispensing system. How will the most consequential change in federal drugpricing policy affect the largest pharmacies and PBMs? Pharmacies and Pharmacy Benefit Managers. to 1:30 p.m.
When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2022. However, some companies had net price gains. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B DrugPricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.
Drug Channels has just obtained new details on the size of the 340B DrugPricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3 d/b/a Drug Channels Institute. billion (+$2.6
When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2022. However, some companies had net price gains. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.
Drug Channels has just obtained new details on the size of the 340B DrugPricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 Every 340B covered entity type experienced double-digit growth, despite drugprices that grew more slowly than overall inflation.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. More than $122 billion in "savings" (offsets) from the current drugpricing reconciliation legislation comes from blocking rebate reform—which never even happened.
Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. It’s the 13th edition of our popular and comprehensive examination of the entire drugpricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before March 28, 2022. d/b/a Drug Channels Institute.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content